Kyverna Therapeutics, Inc. (KYTX) stock forecast and price target
Price $5.05 · data as of November 13, 2026
12-month price target
Average target$30.40
Upside / downside+502.0%
Analysts5
ConsensusStrong buy
Low $25.00Average $30.40High $33.00
Gold marker: average target · white marker: today’s price ($5.05)
Analyst ratings
Strong buy 2Buy 4Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-2.71 | +25.5% | $0 |
| Next fiscal year ends December 31, 2027 | $-3.04 | −12.0% | $18M |
| Next quarter ends December 31, 2026 | $-0.76 | +5.5% | $0 |
| Quarter after ends March 31, 2027 | $-0.79 | — | $500000 |
Consensus of the analysts covering Kyverna Therapeutics, updated daily. In the last 30 days 3 estimates were raised and 2 lowered.
Frequently asked questions
What is the Kyverna Therapeutics stock price target?
The average 12-month target from 5 analysts is $30.40, 502.0% above the current price of $5.05 Targets range from $25.00 to $33.00.
Is Kyverna Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (2 strong buy, 4 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Kyverna Therapeutics expected to earn?
Analysts expect EPS of $-2.71 for the fiscal year ending December 31, 2026 and $-3.04 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.